A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

Fondazione Italiana Linfomi Postgraduate Master Course, Jacopo Olivieri, Federico Mosna, Matteo Pelosini, Angelo Fama, Sara Rattotti, Margherita Giannoccaro, Giuseppe Carli, Maria Chiara Tisi, Simone Ferrero, Nicola Sgherza, Anna Maria Mazzone, Dario Marino, Teresa Calimeri, Giacomo Loseto, Francesco Saraceni, Gabriella Tomei, Simona Sica, Giulia Perali, Katia CodeluppiAtto Billio, Attilio Olivieri, Enrico Orciuolo, Rossella Matera, Piero Maria Stefani, Carlo Borghero, Paola Ghione, Nicola Cascavilla, Francesco Lanza, Patrizia Chiusolo, Silvia Finotto, Irene Federici, Filippo Gherlinzoni, Riccardo Centurioni, Renato Fanin, Francesco Zaja

Research output: Contribution to journalArticle

Abstract

BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P 
Original languageEnglish
Pages (from-to)1814-1822
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

fotemustine
Carmustine
Melphalan
Hematopoietic Stem Cell Transplantation
Cytarabine
Etoposide
Observational Studies
Lymphoma
Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Transplantation Conditioning

Cite this

A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. / Course, Fondazione Italiana Linfomi Postgraduate Master; Olivieri, Jacopo; Mosna, Federico; Pelosini, Matteo; Fama, Angelo; Rattotti, Sara; Giannoccaro, Margherita; Carli, Giuseppe; Tisi, Maria Chiara; Ferrero, Simone; Sgherza, Nicola; Mazzone, Anna Maria; Marino, Dario; Calimeri, Teresa; Loseto, Giacomo; Saraceni, Francesco; Tomei, Gabriella; Sica, Simona; Perali, Giulia; Codeluppi, Katia; Billio, Atto; Olivieri, Attilio; Orciuolo, Enrico; Matera, Rossella; Stefani, Piero Maria; Borghero, Carlo; Ghione, Paola; Cascavilla, Nicola; Lanza, Francesco; Chiusolo, Patrizia; Finotto, Silvia; Federici, Irene; Gherlinzoni, Filippo; Centurioni, Riccardo; Fanin, Renato; Zaja, Francesco.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 9, 01.09.2018, p. 1814-1822.

Research output: Contribution to journalArticle

Course, FILPM, Olivieri, J, Mosna, F, Pelosini, M, Fama, A, Rattotti, S, Giannoccaro, M, Carli, G, Tisi, MC, Ferrero, S, Sgherza, N, Mazzone, AM, Marino, D, Calimeri, T, Loseto, G, Saraceni, F, Tomei, G, Sica, S, Perali, G, Codeluppi, K, Billio, A, Olivieri, A, Orciuolo, E, Matera, R, Stefani, PM, Borghero, C, Ghione, P, Cascavilla, N, Lanza, F, Chiusolo, P, Finotto, S, Federici, I, Gherlinzoni, F, Centurioni, R, Fanin, R & Zaja, F 2018, 'A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi', Biology of Blood and Marrow Transplantation, vol. 24, no. 9, pp. 1814-1822. https://doi.org/10.1016/j.bbmt.2018.05.018
Course, Fondazione Italiana Linfomi Postgraduate Master ; Olivieri, Jacopo ; Mosna, Federico ; Pelosini, Matteo ; Fama, Angelo ; Rattotti, Sara ; Giannoccaro, Margherita ; Carli, Giuseppe ; Tisi, Maria Chiara ; Ferrero, Simone ; Sgherza, Nicola ; Mazzone, Anna Maria ; Marino, Dario ; Calimeri, Teresa ; Loseto, Giacomo ; Saraceni, Francesco ; Tomei, Gabriella ; Sica, Simona ; Perali, Giulia ; Codeluppi, Katia ; Billio, Atto ; Olivieri, Attilio ; Orciuolo, Enrico ; Matera, Rossella ; Stefani, Piero Maria ; Borghero, Carlo ; Ghione, Paola ; Cascavilla, Nicola ; Lanza, Francesco ; Chiusolo, Patrizia ; Finotto, Silvia ; Federici, Irene ; Gherlinzoni, Filippo ; Centurioni, Riccardo ; Fanin, Renato ; Zaja, Francesco. / A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 9. pp. 1814-1822.
@article{c89eb88a6bb94ed984065b934a71eb4a,
title = "A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi",
abstract = "BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27{\%} had Hodgkin lymphoma (HL), 14{\%} indolent non-Hodgkin lymphoma (NHL), and 59{\%} aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P ",
author = "Course, {Fondazione Italiana Linfomi Postgraduate Master} and Jacopo Olivieri and Federico Mosna and Matteo Pelosini and Angelo Fama and Sara Rattotti and Margherita Giannoccaro and Giuseppe Carli and Tisi, {Maria Chiara} and Simone Ferrero and Nicola Sgherza and Mazzone, {Anna Maria} and Dario Marino and Teresa Calimeri and Giacomo Loseto and Francesco Saraceni and Gabriella Tomei and Simona Sica and Giulia Perali and Katia Codeluppi and Atto Billio and Attilio Olivieri and Enrico Orciuolo and Rossella Matera and Stefani, {Piero Maria} and Carlo Borghero and Paola Ghione and Nicola Cascavilla and Francesco Lanza and Patrizia Chiusolo and Silvia Finotto and Irene Federici and Filippo Gherlinzoni and Riccardo Centurioni and Renato Fanin and Francesco Zaja",
note = "Copyright {\circledC} 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2018.05.018",
language = "English",
volume = "24",
pages = "1814--1822",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi

AU - Course, Fondazione Italiana Linfomi Postgraduate Master

AU - Olivieri, Jacopo

AU - Mosna, Federico

AU - Pelosini, Matteo

AU - Fama, Angelo

AU - Rattotti, Sara

AU - Giannoccaro, Margherita

AU - Carli, Giuseppe

AU - Tisi, Maria Chiara

AU - Ferrero, Simone

AU - Sgherza, Nicola

AU - Mazzone, Anna Maria

AU - Marino, Dario

AU - Calimeri, Teresa

AU - Loseto, Giacomo

AU - Saraceni, Francesco

AU - Tomei, Gabriella

AU - Sica, Simona

AU - Perali, Giulia

AU - Codeluppi, Katia

AU - Billio, Atto

AU - Olivieri, Attilio

AU - Orciuolo, Enrico

AU - Matera, Rossella

AU - Stefani, Piero Maria

AU - Borghero, Carlo

AU - Ghione, Paola

AU - Cascavilla, Nicola

AU - Lanza, Francesco

AU - Chiusolo, Patrizia

AU - Finotto, Silvia

AU - Federici, Irene

AU - Gherlinzoni, Filippo

AU - Centurioni, Riccardo

AU - Fanin, Renato

AU - Zaja, Francesco

N1 - Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P 

AB - BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P 

U2 - 10.1016/j.bbmt.2018.05.018

DO - 10.1016/j.bbmt.2018.05.018

M3 - Article

VL - 24

SP - 1814

EP - 1822

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -